Effect of Probiotics on Cytokines in Sepsis in Children
Primary Purpose
Sepsis, Severe
Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
maltose dissolved in distilled water
Sponsored by
About this trial
This is an interventional supportive care trial for Sepsis, Severe
Eligibility Criteria
Inclusion Criteria:
- The study will include children admitted to PICU with sepsis defined as presence of suspected or proven infection with two or more criteria for systemic inflammatory response syndrome (SIRS)
Exclusion Criteria:
- Children having contraindications to start enteral feeding.
- Children with known chronic gastrointestinal illness.
- Children known with immunodeficiency.
- Children on prior steroids or immunotherapy.
Sites / Locations
- Cairo University Faculty of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
CASE, GROUP ONE
CONTROL, GROUP 2
Arm Description
Group 1 (group who will receive probiotics): one sachet contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions), dissolved in 10 ml distilled water twice a day for 7days orally or through nasogastric/orogastric tube depending on clinical status of patients.
GROUP 2 will receive only maltose dissolved in 10 ml of distilled water twice a day for 7 days orally or though nasogastric/orogastric tube depending on clinical status of patients.
Outcomes
Primary Outcome Measures
1- To assess the effect of probiotics on cytokine levels(interleukin 6 and Transforming growth factor-β1) in probiotic group
To assess the effect of probiotics on cytokine levels(interleukin 6 and Transforming growth factor-β1) in probiotic group and To assess the change on cytokine levels (interleukin 6 and Transforming growth factor-β1) from day 1 to 7 in critically ill children with sepsis in two groups.
Secondary Outcome Measures
assessment of other sepsis parameters
Assessment of other sepsis parameters like C-reactive protein ( CRP ) level in relation to prognosis of sepsis in the two groups.
assessment of patient general condition during pediatric intensive care admission
The duration of ventilation, will be assessed in the two groups.
assessment of patient general condition during pediatric intensive care admission
length of stay in the PICU, will be assessed in the two groups.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05467605
Brief Title
Effect of Probiotics on Cytokines in Sepsis in Children
Official Title
Effect of Probiotics on Interleukin 6 and Transforming Growth Factor-βLevels in Critically Ill Children With Sepsis
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
July 22, 2022 (Actual)
Primary Completion Date
January 20, 2023 (Actual)
Study Completion Date
February 5, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To assess the effect of probiotics on cytokine's level(interleukin 6 and Transforming growth factor-β1)in children admitted to PICU with sepsis.
Detailed Description
Sepsis, defined as an infection with deregulated host response leading to life-threatening organ dysfunction. Historically, the term sepsis has been used to characterize life-threatening infections usually caused by bacterial pathogens if untreated progress to shock and death, It contributes to 19% of all deaths globally, with the highest age-specific incidence in children younger than 5 years of age. Pediatric sepsis resulted in 0.7% of all hospital encounters. Epidemiologic studies found an incidence of pediatric sepsis in up to 8% of all pediatric intensive care unit (PICU) admissions, contributing to 1in 4 deaths in PICUs.
Despite many advances in diagnosis and management, sepsis is associated with significant morbidity and mortality in pediatric population. The pathophysiology of systemic inflammatory response syndrome (SIRS)and sepsis is characterized by hyperactive and deregulated endogenous inflammatory mediators in a sequential manner resulting in a cytokine cascade.
Cytokines are regulators of the immune response to infection and play a key role in regulating inflammation and trauma. There are two types of cytokines. Pro-inflammatory cytokines and anti-inflammatory cytokines.
Pro-inflammatory cytokines(tumor necrosis factor [TNF]-α, interferon-γ, interleukin[IL]-1α, IL-1β, IL-6, IL-8, IL-12, IL-17) are important for initiation of an effective inflammatory response against pathogens, whereas their excess production can lead to multiple organ dysfunction syndrome (MODS) and mortality, on the other side, anti-inflammatory cytokines (IL-4, IL-10, IL-13,transforming growth factor [TGF]-β) are required for controlling and down-regulating the inflammatory response and if severe can lead to depression of the immune system.
The levels of these cytokines rise within few hours of onset of sepsis and remain elevated for days together depending on severity and duration of sepsis, baseline host factors, timing of sampling relative to onset of sepsis/septic shock, and inter-individual variation.
The gastrointestinal system seems to play a key role in the pathogenesis MODS owing to a breakdown of intestinal barrier function and increased translocation of bacteria and bacterial components into the systemic circulation.
During critical illness, alterations occur in gut micro flora owing to change in circulating stress hormones, gut ischemia, immune suppression, the use of antibiotics, and lack of nutrients due to delay in starting enteral feeding.
Probiotics are living micro-organisms that, when administered in adequate amounts, can help maintain the integrity of the intestinal barrier function by modulating the immune response. Such administration has been included in the management of critically ill patients as a therapeutic approach.
Various studies highlighted that probiotics can modulate intestinal micro biota by colonizing human GIT, preventing overgrowth of pathogens, normalizing altered intestinal flora, reducing bacterial translocation, influencing immune system, and balancing control of pro-inflammatory and anti-inflammatory Cytokines.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Severe
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CASE, GROUP ONE
Arm Type
Active Comparator
Arm Description
Group 1 (group who will receive probiotics): one sachet contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions), dissolved in 10 ml distilled water twice a day for 7days orally or through nasogastric/orogastric tube depending on clinical status of patients.
Arm Title
CONTROL, GROUP 2
Arm Type
Placebo Comparator
Arm Description
GROUP 2 will receive only maltose dissolved in 10 ml of distilled water twice a day for 7 days orally or though nasogastric/orogastric tube depending on clinical status of patients.
Intervention Type
Dietary Supplement
Intervention Name(s)
probiotics( Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
Other Intervention Name(s)
LACTEOL FORTE
Intervention Description
therapeutic intervention, Children will be randomized into two groups using sealed envelopes on admission after meeting inclusion criteria, group ONE will receive multi strain probiotic product which contains(Lactobacillus acidophilus, lactobacillus delbruekii and lactobacillus fermentum 10 billions),
Intervention Type
Other
Intervention Name(s)
maltose dissolved in distilled water
Intervention Description
the other group placebo (GROUP TWO ) will receive maltose dissolved in 10 ml distilled water .
Primary Outcome Measure Information:
Title
1- To assess the effect of probiotics on cytokine levels(interleukin 6 and Transforming growth factor-β1) in probiotic group
Description
To assess the effect of probiotics on cytokine levels(interleukin 6 and Transforming growth factor-β1) in probiotic group and To assess the change on cytokine levels (interleukin 6 and Transforming growth factor-β1) from day 1 to 7 in critically ill children with sepsis in two groups.
Time Frame
one week
Secondary Outcome Measure Information:
Title
assessment of other sepsis parameters
Description
Assessment of other sepsis parameters like C-reactive protein ( CRP ) level in relation to prognosis of sepsis in the two groups.
Time Frame
up to 2 weeks
Title
assessment of patient general condition during pediatric intensive care admission
Description
The duration of ventilation, will be assessed in the two groups.
Time Frame
through admission till discharge from PICU up to one month
Title
assessment of patient general condition during pediatric intensive care admission
Description
length of stay in the PICU, will be assessed in the two groups.
Time Frame
through admission till discharge from PICU up to one month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Days
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The study will include children admitted to PICU with sepsis defined as presence of suspected or proven infection with two or more criteria for systemic inflammatory response syndrome (SIRS)
Exclusion Criteria:
Children having contraindications to start enteral feeding.
Children with known chronic gastrointestinal illness.
Children known with immunodeficiency.
Children on prior steroids or immunotherapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
AYMAN EMIL, MD
Organizational Affiliation
Professor of Pediatrics, Cairo University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
HANAA RADY, MD
Organizational Affiliation
Professor of Pediatrics, Cairo University
Official's Role
Study Director
Facility Information:
Facility Name
Cairo University Faculty of Medicine
City
Cairo
Country
Egypt
12. IPD Sharing Statement
Citations:
PubMed Identifier
29957709
Citation
Angurana SK, Bansal A, Singhi S, Aggarwal R, Jayashree M, Salaria M, Mangat NK. Evaluation of Effect of Probiotics on Cytokine Levels in Critically Ill Children With Severe Sepsis: A Double-Blind, Placebo-Controlled Trial. Crit Care Med. 2018 Oct;46(10):1656-1664. doi: 10.1097/CCM.0000000000003279.
Results Reference
result
PubMed Identifier
24292568
Citation
Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti PS, Nagarkatti M. Role of cytokines as a double-edged sword in sepsis. In Vivo. 2013 Nov-Dec;27(6):669-84.
Results Reference
result
Learn more about this trial
Effect of Probiotics on Cytokines in Sepsis in Children
We'll reach out to this number within 24 hrs